Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment of PERitoneal dissemination in Stomach Cancer patients with cytOreductive surgery and hyperthermic intraPEritoneal chemotherapy: the PERISCOPE II study.

X
Trial Profile

Treatment of PERitoneal dissemination in Stomach Cancer patients with cytOreductive surgery and hyperthermic intraPEritoneal chemotherapy: the PERISCOPE II study.

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Docetaxel (Primary) ; Oxaliplatin
  • Indications Adenocarcinoma; Gastric cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Acronyms PERISCOPE II-study; PERISCOPEII
  • Most Recent Events

    • 14 Feb 2022 Planned End Date changed from 14 Jul 2021 to 1 Oct 2029.
    • 14 Feb 2022 Planned primary completion date changed from 1 Oct 2021 to 1 Oct 2026.
    • 06 May 2021 Planned number of patients changed from 106 to 182.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top